Press Releases

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.055 per share, payable on December 16, 2008 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal year 2009 on Thursday, November 6, 2008 at approximately 8:00 a.m....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired Laboratorios Diba, S.A. for approximately $25 million in cash. Based in Guadalajara, Mexico, privately-held...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Perrigo Chairman and CEO Joseph C. Papa will present at the JMP Securities 2008 Healthcare Focus Conference on Monday, October 6, at...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the Hatch-Waxman litigation relating to Miconazole Nitrate Vaginal Cream and Suppository between Johnson & Johnson and Perrigo...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired JB Laboratories for approximately $44 million in cash. Based in Holland, Michigan, privately-held JB Laboratories is...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's CFO will present at the Merrill Lynch Global Pharmaceutical Conference on Tuesday, September 16 at the Merrill...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it has acquired the exclusive U.S. rights to sell and distribute Levocetirizine tablets, the generic version of UCB's Xyzal®...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fourth quarter and full year ended June 28, 2008. Perrigo's Chairman and CEO Joseph C. Papa commented, "For the third...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on September 16, 2008 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it began shipping Famotidine Complete chewable tablets (famotidine 10 mg; calcium carbonate 800mg; magnesium hydroxide 165 mg) to...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Judy Brown, Perrigo's Chief Financial Officer, will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Bank of America Specialty Pharmaceuticals Conference on Thursday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its fiscal year 2008 on Monday, August 18, 2008 at approximately 8:00 a.m. (ET). The Company...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO), the world's largest manufacturer of over-the-counter healthcare products sold under the store-brand label, announced today its intent to invest $10.5...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors has appointed Ellen R. Hoffing as a new director of the Company. Joseph C. Papa, Perrigo's Chairman,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Cetirizine Hydrochloride Syrup...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for Fluocinonide Cream 0.1%, a generic version of VANOS® Cream 0.1%. The...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has entered into a collaborative agreement with Cobrek Pharmaceuticals, a newly formed entity of Pentech Pharmaceuticals Inc., a...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph C. Papa, Perrigo's Chairman and CEO will present at the Citi Investment Research Global Health Care Conference on Wednesday,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its third quarter fiscal year 2008 and nine months ended March 29, 2008. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on June 20, 2008 to shareholders of record on May...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market over-the-counter (OTC) Nicotine Polacrilex...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its third quarter fiscal 2008 on Tuesday, May 6, 2008 at approximately 8:00 a.m. (ET). The...

ALLEGAN, Mich., April 21 /PRNewswire-FirstCall/ .- Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has filed an Abbreviated New Drug Application (ANDA) for over-the-counter...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market over-the-counter (OTC)...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 12th Annual Sidoti Emerging Growth Institutional Investor Forum on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the United States District Court for the District of New Jersey has denied Connetics Corporation's motion for a preliminary...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its partner, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA), has received final approval from the U.S. Food and Drug...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has begun shipping 20 mg Omeprazole delayed released tablets to its retail customers. This product delivers the same medicine at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Joseph Papa, Perrigo's Chairman and CEO will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device...

-- Second quarter revenue increased $65 million, or 17 percent, to $435 million -- GAAP net income increased 63 percent to $34 million, or $0.36 per share -- Second quarter cash provided by...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that the Board of Directors has authorized the repurchase of $150 million of the Company's common stock through February 1, 2010...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its second quarter fiscal 2008 on Tuesday, February 5, 2008 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has acquired Galpharm Healthcare, Ltd. for $86 million in cash. Based in Barnsley, Yorkshire, United Kingdom, privately-held...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that Perrigo Chairman and CEO Joseph C. Papa will present at the 26th Annual JPMorgan Healthcare Conference on Wednesday, January 9, at...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to Dexcel Pharma Technologies, Ltd. for 20 mg Omeprazole...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced results for its fiscal year 2008 first quarter that ended September 29, 2007. Perrigo Company (in thousands, except per share...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that Dexcel Pharma Technologies, Ltd. ("Dexcel"), Perrigo's partner for store brand OTC 20mg Omeprazole delayed release tablet, has...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors appointed President and Chief Executive Officer, Joseph C. Papa, to be Chairman of its Board of Directors....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.05 per share, payable on December 18, 2007 to shareholders of record on...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it will release financial results for its first quarter fiscal 2008 on Thursday, November 1, 2007 at approximately 8:00 a.m. (ET)....

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of...

The Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that it has received final approval from the U.S. Food and Drug Administration to manufacture and market Ciclopirox Topical Solution,...

Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) today announced that President and CEO, Joseph C. Papa and the Perrigo management team will provide a review of the Company business for the financial...